Global DTaP and Tdap Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global DTaP and Tdap Vaccines Market Size and Outlook 2025-31

The global DTaP and Tdap Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEFs total procurement. Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries. The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the DTaP and Tdap Vaccines Industry Forecast looks at past sales and reviews total world DTaP and Tdap Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected DTaP and Tdap Vaccines sales for 2025 through 2031. With DTaP and Tdap Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DTaP and Tdap Vaccines industry. This Insight Report provides a comprehensive analysis of the global DTaP and Tdap Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on DTaP and Tdap Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global DTaP and Tdap Vaccines market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DTaP and Tdap Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DTaP and Tdap Vaccines. This report presents a comprehensive overview, market shares, and growth opportunities of DTaP and Tdap Vaccines market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; DTaP &nbsp;&nbsp;&nbsp; Td &nbsp;&nbsp;&nbsp; Tdap Segmentation by Application: &nbsp;&nbsp;&nbsp; Adult &nbsp;&nbsp;&nbsp; Pediatric This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Sanofi Pasteur &nbsp;&nbsp;&nbsp; GlaxoSmithKline &nbsp;&nbsp;&nbsp; Protein Sciences Corporation &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Seqirus &nbsp;&nbsp;&nbsp; Merck Sharp & Dohme Corp &nbsp;&nbsp;&nbsp; Astellas Pharma US, Inc &nbsp;&nbsp;&nbsp; Pfizer Inc &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Lanzhou Institute of Biological Products Co., Ltd &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; Emergent BioSolutions Inc Key Questions Addressed in this Report What is the 10-year outlook for the global DTaP and Tdap Vaccines market? What factors are driving DTaP and Tdap Vaccines market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do DTaP and Tdap Vaccines market opportunities vary by end market size? How does DTaP and Tdap Vaccines break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global DTaP and Tdap Vaccines Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for DTaP and Tdap Vaccines by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for DTaP and Tdap Vaccines by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 DTaP and Tdap Vaccines Segment by Type &nbsp;2.2.1 DTaP &nbsp;2.2.2 Td &nbsp;2.2.3 Tdap &nbsp;2.3 DTaP and Tdap Vaccines Sales by Type &nbsp;2.3.1 Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global DTaP and Tdap Vaccines Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global DTaP and Tdap Vaccines Sale Price by Type (2020-2025) &nbsp;2.4 DTaP and Tdap Vaccines Segment by Application &nbsp;2.4.1 Adult &nbsp;2.4.2 Pediatric &nbsp;2.5 DTaP and Tdap Vaccines Sales by Application &nbsp;2.5.1 Global DTaP and Tdap Vaccines Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global DTaP and Tdap Vaccines Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global DTaP and Tdap Vaccines Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global DTaP and Tdap Vaccines Breakdown Data by Company &nbsp;3.1.1 Global DTaP and Tdap Vaccines Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Company (2020-2025) &nbsp;3.2 Global DTaP and Tdap Vaccines Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global DTaP and Tdap Vaccines Revenue by Company (2020-2025) &nbsp;3.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global DTaP and Tdap Vaccines Sale Price by Company &nbsp;3.4 Key Manufacturers DTaP and Tdap Vaccines Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers DTaP and Tdap Vaccines Product Location Distribution &nbsp;3.4.2 Players DTaP and Tdap Vaccines Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for DTaP and Tdap Vaccines by Geographic Region &nbsp;4.1 World Historic DTaP and Tdap Vaccines Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global DTaP and Tdap Vaccines Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global DTaP and Tdap Vaccines Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic DTaP and Tdap Vaccines Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global DTaP and Tdap Vaccines Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global DTaP and Tdap Vaccines Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas DTaP and Tdap Vaccines Sales Growth &nbsp;4.4 APAC DTaP and Tdap Vaccines Sales Growth &nbsp;4.5 Europe DTaP and Tdap Vaccines Sales Growth &nbsp;4.6 Middle East & Africa DTaP and Tdap Vaccines Sales Growth 5 Americas &nbsp;5.1 Americas DTaP and Tdap Vaccines Sales by Country &nbsp;5.1.1 Americas DTaP and Tdap Vaccines Sales by Country (2020-2025) &nbsp;5.1.2 Americas DTaP and Tdap Vaccines Revenue by Country (2020-2025) &nbsp;5.2 Americas DTaP and Tdap Vaccines Sales by Type (2020-2025) &nbsp;5.3 Americas DTaP and Tdap Vaccines Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC DTaP and Tdap Vaccines Sales by Region &nbsp;6.1.1 APAC DTaP and Tdap Vaccines Sales by Region (2020-2025) &nbsp;6.1.2 APAC DTaP and Tdap Vaccines Revenue by Region (2020-2025) &nbsp;6.2 APAC DTaP and Tdap Vaccines Sales by Type (2020-2025) &nbsp;6.3 APAC DTaP and Tdap Vaccines Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe DTaP and Tdap Vaccines by Country &nbsp;7.1.1 Europe DTaP and Tdap Vaccines Sales by Country (2020-2025) &nbsp;7.1.2 Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025) &nbsp;7.2 Europe DTaP and Tdap Vaccines Sales by Type (2020-2025) &nbsp;7.3 Europe DTaP and Tdap Vaccines Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa DTaP and Tdap Vaccines by Country &nbsp;8.1.1 Middle East & Africa DTaP and Tdap Vaccines Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa DTaP and Tdap Vaccines Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa DTaP and Tdap Vaccines Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa DTaP and Tdap Vaccines Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines &nbsp;10.3 Manufacturing Process Analysis of DTaP and Tdap Vaccines &nbsp;10.4 Industry Chain Structure of DTaP and Tdap Vaccines 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 DTaP and Tdap Vaccines Distributors &nbsp;11.3 DTaP and Tdap Vaccines Customer 12 World Forecast Review for DTaP and Tdap Vaccines by Geographic Region &nbsp;12.1 Global DTaP and Tdap Vaccines Market Size Forecast by Region &nbsp;12.1.1 Global DTaP and Tdap Vaccines Forecast by Region (2026-2031) &nbsp;12.1.2 Global DTaP and Tdap Vaccines Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global DTaP and Tdap Vaccines Forecast by Type (2026-2031) &nbsp;12.7 Global DTaP and Tdap Vaccines Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Sanofi Pasteur &nbsp;13.1.1 Sanofi Pasteur Company Information &nbsp;13.1.2 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Sanofi Pasteur Main Business Overview &nbsp;13.1.5 Sanofi Pasteur Latest Developments &nbsp;13.2 GlaxoSmithKline &nbsp;13.2.1 GlaxoSmithKline Company Information &nbsp;13.2.2 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 GlaxoSmithKline Main Business Overview &nbsp;13.2.5 GlaxoSmithKline Latest Developments &nbsp;13.3 Protein Sciences Corporation &nbsp;13.3.1 Protein Sciences Corporation Company Information &nbsp;13.3.2 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Protein Sciences Corporation Main Business Overview &nbsp;13.3.5 Protein Sciences Corporation Latest Developments &nbsp;13.4 Novartis AG &nbsp;13.4.1 Novartis AG Company Information &nbsp;13.4.2 Novartis AG DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Novartis AG Main Business Overview &nbsp;13.4.5 Novartis AG Latest Developments &nbsp;13.5 Seqirus &nbsp;13.5.1 Seqirus Company Information &nbsp;13.5.2 Seqirus DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Seqirus Main Business Overview &nbsp;13.5.5 Seqirus Latest Developments &nbsp;13.6 Merck Sharp & Dohme Corp &nbsp;13.6.1 Merck Sharp & Dohme Corp Company Information &nbsp;13.6.2 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Merck Sharp & Dohme Corp Main Business Overview &nbsp;13.6.5 Merck Sharp & Dohme Corp Latest Developments &nbsp;13.7 Astellas Pharma US, Inc &nbsp;13.7.1 Astellas Pharma US, Inc Company Information &nbsp;13.7.2 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Astellas Pharma US, Inc Main Business Overview &nbsp;13.7.5 Astellas Pharma US, Inc Latest Developments &nbsp;13.8 Pfizer Inc &nbsp;13.8.1 Pfizer Inc Company Information &nbsp;13.8.2 Pfizer Inc DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Pfizer Inc Main Business Overview &nbsp;13.8.5 Pfizer Inc Latest Developments &nbsp;13.9 Johnson & Johnson &nbsp;13.9.1 Johnson & Johnson Company Information &nbsp;13.9.2 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.9.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Johnson & Johnson Main Business Overview &nbsp;13.9.5 Johnson & Johnson Latest Developments &nbsp;13.10 Lanzhou Institute of Biological Products Co., Ltd &nbsp;13.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information &nbsp;13.10.2 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview &nbsp;13.10.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments &nbsp;13.11 AstraZeneca &nbsp;13.11.1 AstraZeneca Company Information &nbsp;13.11.2 AstraZeneca DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.11.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 AstraZeneca Main Business Overview &nbsp;13.11.5 AstraZeneca Latest Developments &nbsp;13.12 Emergent BioSolutions Inc &nbsp;13.12.1 Emergent BioSolutions Inc Company Information &nbsp;13.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolios and Specifications &nbsp;13.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Emergent BioSolutions Inc Main Business Overview &nbsp;13.12.5 Emergent BioSolutions Inc Latest Developments 14 Research Findings and Conclusion

Report	Global DTaP and Tdap Vaccines Market Growth 2025-2031
Selected License	Multi ID: LPI23215

Buyer Information

Order Summary